Hayhow, Thomas G. http://orcid.org/0000-0002-8555-375X
Williamson, Beth
Lawson, Mandy
Cureton, Natalie
Braybrooke, Erin L.
Campbell, Andrew
Carbajo, Rodrigo J. http://orcid.org/0000-0002-0312-6499
Cheraghchi-Bashi, Azadeh
Chiarparin, Elisabetta
Diène, Coura R.
Fallan, Charlene
Fisher, David I. http://orcid.org/0009-0003-6681-1877
Goldberg, Frederick W. http://orcid.org/0000-0002-4874-1700
Hopcroft, Lorna http://orcid.org/0000-0003-3689-7609
Hopcroft, Philip http://orcid.org/0000-0002-7445-2910
Jackson, Anne
Kettle, Jason G.
Klinowska, Teresa
Künzel, Ulrike
Lamont, Gillian
Lewis, Hilary J. http://orcid.org/0000-0002-4661-4564
Maglennon, Gareth
Martin, Scott
Gutierrez, Pablo Morentin
Morrow, Christopher J. http://orcid.org/0000-0003-1524-9426
Nikolaou, Myria
Nissink, J. Willem M. http://orcid.org/0000-0003-2572-9140
O’Shea, Patrick
Polanski, Radoslaw
Schade, Markus http://orcid.org/0000-0002-5538-5767
Scott, James S.
Smith, Aaron http://orcid.org/0000-0003-3768-8550
Weber, Judith http://orcid.org/0000-0003-1290-2629
Wilson, Joanne
Yang, Bin
Crafter, Claire http://orcid.org/0000-0001-6566-0868
Article History
Received: 17 January 2024
Accepted: 24 April 2024
First Online: 13 May 2024
Competing interests
: The authors declare no competing interests.
: All animal work was conducted according to AstraZeneca’s Global Bioethics Policy (), in accordance with the PREPARE guidelines and reported in line with the ARRIVE guidelines. CTC-174 studies were performed internally at AstraZeneca in the United Kingdom, under the authorisation of Home Office License PP3292652. Protocols were reviewed by internal review teams independent of the project to ensure compliance to licence PP3292652. We have complied with all relevant ethical regulations for animal use.